NCT05790473 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Chaoui R, Benoit B, Mitkowska-Wozniak H, Heling KS, Nicolaides KH
Assessment of intracranial translucency (IT) in the detection of spina bifida at the 11-13-week scan. Ultrasound Obstet Gynecol. 2009 Sep;34(3):249-52. doi: 10.1002/uog.7329.
Chen Z, Liu Z, Du M, Wang Z
Artificial Intelligence in Obstetric Ultrasound: An Update and Future Applications. Front Med (Lausanne). 2021 Aug 27;8:733468. doi: 10.3389/fmed.2021.733468. eCollection 2021.
Drukker L, Noble JA, Papageorghiou AT
Introduction to artificial intelligence in ultrasound imaging in obstetrics and gynecology. Ultrasound Obstet Gynecol. 2020 Oct;56(4):498-505. doi: 10.1002/uog.22122.
Garcia-Rodriguez R, Garcia-Delgado R, Romero-Requejo A, Medina-Castellano M, Garcia-Hernandez JA, Gonzalez-Martin JM, Sepulveda W
First-trimester cystic posterior fossa: reference ranges, associated findings, and pregnancy outcomes. J Matern Fetal Neonatal Med. 2021 Mar;34(6):933-942. doi: 10.1080/14767058.2019.1622673. Epub 2019 Jun 4.

Artificial Intelligence Algorithm for the Screening of Abnormal Fetal Brain Findings at First Trimester Ultrasound Scan

Clinical trial NCT05790473 - References